UCB-MSCs (Yonsei University College of Medicine/Daewoong Pharmaceutical/Kangstem Biotech)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameUCB-MSCs (Yonsei University College of Medicine/Daewoong Pharmaceutical/Kangstem Biotech)
Drug Alias Nameumbilical cord blood stem cell-derived therapy (Yonsei University College of Medicine/Daewoong Pharmaceutical/Kangstem Biotech)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Umbilical cord stem cell therapyCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsEpidermolysis Bullosa Dystrophica
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesYonsei University
China Registration ClassN/A

Develop Information

Active CompaniesDaewoong Pharmaceutical Co LtdYonsei UniversityKangstem Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsEpidermolysis Bullosa Dystrophica
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A